PAHC — PHIBRO ANIMAL HEALTH CORP

Nasdaq · Health Care · Pharmaceuticals · CIK 1069899 ·
Last close
$36.95
Market Cap
$778.49M
52W High
$58.49
52W Low
$28.13
ADV30
276,060
Next earnings
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 383,543,000 125,675,000 44,653,000 24,024,000 1,445,118,000 54,929,000 1,083,291,000
Dec 2025 373,910,000 132,656,000 50,326,000 27,459,000 1,405,553,000 55,486,000 1,073,192,000
Sep 2025 363,893,000 119,783,000 51,260,000 26,527,000 1,385,524,000 72,769,000 1,073,843,000
Jun 2025 378,697,000 110,009,000 33,718,000 17,224,000 1,360,900,000 68,039,000 1,075,218,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$93,080,000
Investing CF
$-63,483,000
Financing CF
$-42,634,000
CapEx
$-45,791,000
Dividends Paid
$-19,457,000
Buybacks
EPS Diluted TTM
$2.25
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$316,959,000
Inventory
$517,347,000
Receivables
$215,872,000
ST Investments
$19,022,000
EBIT TTM
$167,579,000
Pretax Income TTM
$126,227,000
Interest Exp TTM
$41,352,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,500,043,008
EBITDA
$234,754,000
Free Cash Flow
$-17,678,250
Enterprise Value
$2,189,124,864
Total Cash
$78,138,000
Total Debt
$788,678,976
Shares Out
21,068,682
Trailing EPS
$2.33
Book Value
$8.92
ROE
30.3%
ROA
8.4%
Div Yield
1.32%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 1,296,215,000 110,465,000 48,264,000 1,360,900,000 1,075,218,000 80,124,000
Jun 2024 1,017,679,000 53,315,000 2,416,000 982,184,000 725,543,000 87,594,000
Jun 2023 977,889,000 71,847,000 32,606,000 971,397,000 688,888,000 13,310,000
Jun 2022 942,261,000 78,986,000 49,175,000 931,699,000 669,257,000 31,649,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$3.34

Peers — same industry

TickerNameMarket CapLastDaily %
KURA Kura Oncology, Inc. $792.76M $8.93
ANNX Annexon, Inc. $796.27M $4.86
CYRX Cryoport, Inc. $752.51M $14.93
NIKA NIKA PHARMACEUTICALS, INC $806.33M $0.77
DSGN Design Therapeutics, Inc. $750.73M $12.02

News headlines (Yahoo Finance, 1h cache)

ALGN Stock Up Post Q2 Earnings and Revenue Beat, Margins Rise
2026-07-30 16:34 · Yahoo
Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Beats Revenue Estimates
2026-07-28 23:30 · Yahoo
PAHC vs. SYK: Which Stock Is the Better Value Option?
2026-07-27 15:40 · Yahoo
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
2026-07-22 13:40 · Yahoo
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
2026-07-15 12:48 · Yahoo
3 of Wall Street’s Favorite Stocks with Warning Signs
2026-07-13 14:06 · Yahoo
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
2026-07-09 15:40 · Yahoo
Phibro Animal Health (PAHC) Leaves Russell Indexes, Is The Stock A Bargain?
2026-07-09 15:10 · Yahoo
Phibro Animal Health (PAHC) Stock Looks Reasonable On Value But Stretched After 138% Gain
2026-07-09 10:12 · Yahoo
Phibro Animal Health (PAHC) Stock Loses Russell Index Spots And Investor Visibility
2026-07-09 06:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.